Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aceragen Inc ACGN

Healthcare Biotechnology
Aceragen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and... see more

Recent & Breaking News (NDAQ:ACGN)

Aceragen, Inc. to Delist from The Nasdaq Stock Market

GlobeNewswire August 4, 2023

Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

GlobeNewswire May 30, 2023

Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study

GlobeNewswire February 6, 2023

Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook

GlobeNewswire January 17, 2023

Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 14, 2022

Idera Pharmaceuticals Acquires Aceragen

GlobeNewswire September 28, 2022

Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results

GlobeNewswire August 9, 2022

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC

GlobeNewswire May 17, 2022

Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 5, 2022

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 31, 2022

Idera Pharmaceuticals Announces Tilsotolimod Updates

GlobeNewswire December 14, 2021

Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2021

Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 9, 2021

Idera Pharmaceuticals Announces Corporate Updates

GlobeNewswire May 18, 2021

Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire April 29, 2021

Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma

GlobeNewswire March 18, 2021

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

GlobeNewswire March 1, 2021

Idera Pharmaceuticals to Present at Upcoming Conferences

GlobeNewswire January 11, 2021

Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million

GlobeNewswire December 15, 2020

Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire October 29, 2020